These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 30026184)

  • 21. Vascular remodeling underlies rebleeding in hemophilic arthropathy.
    Bhat V; Olmer M; Joshi S; Durden DL; Cramer TJ; Barnes RF; Ball ST; Hughes TH; Silva M; Luck JV; Moore RE; Mosnier LO; von Drygalski A
    Am J Hematol; 2015 Nov; 90(11):1027-35. PubMed ID: 26257191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice.
    Mao SS; Holahan MA; Bailey C; Wu G; Colussi D; Carroll SS; Cook JJ
    Blood Coagul Fibrinolysis; 2005 Sep; 16(6):407-15. PubMed ID: 16093731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII.
    Antovic JP; Antovic A; He S; Tengborn L; Blombäck M
    Haemophilia; 2002 Nov; 8(6):781-6. PubMed ID: 12410647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of thrombin-activatable fibrinolysis inhibitor in allergic bronchial asthma.
    Fujiwara A; Taguchi O; Takagi T; D'Alessandro-Gabazza CN; Boveda-Ruiz D; Toda M; Yasukawa A; Matsushima Y; Miyake Y; Kobayashi H; Kobayashi T; Gil-Bernabe P; Naito M; Yoshida M; Morser J; Takei Y; Gabazza EC
    Lung; 2012 Apr; 190(2):189-98. PubMed ID: 22037793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation of a stable thrombin-activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation.
    Zhou X; Declerck PJ
    J Thromb Haemost; 2015 Jun; 13(6):1084-9. PubMed ID: 25773535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice.
    Renckens R; Roelofs JJ; ter Horst SA; van 't Veer C; Havik SR; Florquin S; Wagenaar GT; Meijers JC; van der Poll T
    J Immunol; 2005 Nov; 175(10):6764-71. PubMed ID: 16272333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.
    Foley JH; Kim P; Nesheim ME
    J Biol Chem; 2008 Apr; 283(14):8863-7. PubMed ID: 18252711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of TAFI increases brain damage and microparticle generation after thrombolytic therapy in ischemic stroke.
    Orbe J; Alexandru N; Roncal C; Belzunce M; Bibiot P; Rodriguez JA; Meijers JC; Georgescu A; Paramo JA
    Thromb Res; 2015 Aug; 136(2):445-50. PubMed ID: 26118976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor.
    te Velde EA; Wagenaar GT; Reijerkerk A; Roose-Girma M; Borel Rinkes IH; Voest EE; Bouma BN; Gebbink MF; Meijers JC
    J Thromb Haemost; 2003 Oct; 1(10):2087-96. PubMed ID: 14521589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
    Jönsson Rylander AC; Lindgren A; Deinum J; Bergström GM; Böttcher G; Kalies I; Wåhlander K
    J Thromb Haemost; 2017 Apr; 15(4):758-769. PubMed ID: 28135035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombin-activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis.
    Mook-Kanamori BB; Valls Serón M; Geldhoff M; Havik SR; van der Ende A; Baas F; van der Poll T; Meijers JC; P Morgan B; Brouwer MC; van de Beek D
    J Thromb Haemost; 2015 Nov; 13(11):2076-86. PubMed ID: 26340319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secreted Bacillus anthracis proteases target the host fibrinolytic system.
    Chung MC; Jorgensen SC; Tonry JH; Kashanchi F; Bailey C; Popov S
    FEMS Immunol Med Microbiol; 2011 Jul; 62(2):173-81. PubMed ID: 21395696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A.
    Lisman T; Mosnier LO; Lambert T; Mauser-Bunschoten EP; Meijers JC; Nieuwenhuis HK; de Groot PG
    Blood; 2002 Jan; 99(1):175-9. PubMed ID: 11756168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system.
    Suzuki Y; Sano H; Mochizuki L; Honkura N; Urano T
    Blood Adv; 2020 Nov; 4(21):5501-5511. PubMed ID: 33166409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies.
    Matsumoto T; Nogami K; Ogiwara K; Shima M
    Thromb Haemost; 2012 Feb; 107(2):288-301. PubMed ID: 22234708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased zymogen activity of thrombin-activatable fibrinolysis inhibitor prolongs clot lysis.
    Mishra N; Buelens K; Theyskens S; Compernolle G; Gils A; Declerck PJ
    J Thromb Haemost; 2012 Jun; 10(6):1091-9. PubMed ID: 22498006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful treatment of acquired hemophilia A associated with immune thrombocytopenia and joint hemarthrosis: A case report and literature review.
    Wei F
    Medicine (Baltimore); 2018 Sep; 97(38):e12044. PubMed ID: 30235659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New insights into factors affecting clot stability: A role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R).
    Bouma BN; Meijers JC
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):13-9. PubMed ID: 14872415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-α pathway.
    Haxaire C; Hakobyan N; Pannellini T; Carballo C; McIlwain D; Mak TW; Rodeo S; Acharya S; Li D; Szymonifka J; Song X; Monette S; Srivastava A; Salmon JE; Blobel CP
    Blood; 2018 Sep; 132(10):1064-1074. PubMed ID: 29776906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a.
    Semeraro F; Ammollo CT; Gils A; Declerck PJ; Colucci M
    J Thromb Haemost; 2013 Dec; 11(12):2137-47. PubMed ID: 24134522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.